Hepatitis B Vaccine and Immunoglobulin: Key Concepts
Open Access
- 4 June 2019
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 7 (X), 1-7
- https://doi.org/10.14218/jcth.2018.00037
Abstract
Hepatitis B virus (HBV) immunization is safe and has been accepted worldwide as a routine practice. The target of such vaccination is to induce the immune response in the host, resulting in the prevention of replication of HBV. There are several immunological and clinical factors which determine the clinical efficacy and safety of the HBV vaccine. In this article we have highlighted the response of the host immune system to HBV vaccination (immunogenicity), efficacy, and safety of the vaccine, issues with booster dosing, paths of development (preclinical and clinical) of the HBV vaccine, novel and upcoming strategies for improvement of HBV vaccination, and the concept of therapeutic HBV vaccination. The different aspects and regulatory recommendations pertaining to HBV vaccine development are also discussed. The new strategies for improvement of HBV vaccination include pre-S1 and pre-S2 portions of the HBV surface antigen, increasing the antigen dose, accelerated vaccination schedules, alternative vaccination route, use of adjuvants like immunostimulatory DNA sequences, etc. Therapeutic vaccination is being explored for initiation of a multifunctional and multispecific T cell response against the major HBV antigens and also effective activation of humoral immunity for viral control.Keywords
This publication has 48 references indexed in Scilit:
- Use of Pre-S Protein-Containing Hepatitis B Virus Surface Antigens and a Powerful Adjuvant To Develop an Immune Therapy for Chronic Hepatitis B Virus InfectionClinical and Vaccine Immunology, 2012
- Can specific heterologous immunity boost hepatitis B vaccine responses?The Journal of Infectious Diseases, 2008
- Hepatitis B immune globulinDrugs of Today, 2007
- Hepatitis B virus S gene escape mutantsAsian Journal of Transfusion Science, 2007
- In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis BJournal of Clinical Virology, 2005
- A review of hepatitis B vaccinationExpert Opinion on Drug Safety, 2003
- Safety and immunogenicity of a combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B vaccine administered at two, four and six months of age compared with monovalent hepatitis B vaccine administered at birth, one month and six months of ageThe Pediatric Infectious Disease Journal, 2002
- Vaccination Against Hepatitis B Virus in Cirrhotic Patients on Liver Transplant Waiting ListLiver Transplantation, 2000
- Hepatitis B vaccine boosting: the debate continuesThe Lancet, 1995
- Severe acute hepatitis B infection after vaccinationThe Lancet, 1994